US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ARS PHARMACEUTICALS INC

17.93

-0.4250-2.32%

Volume:308.79K

Turnover:5.58M

Market Cap:1.76B

PE:-111.48

High:18.50

Open:18.50

Low:17.88

Close:18.35

Loading ...

Overview Company News Filings

ARS Pharmaceuticals Falls After Wider-Than-Expected 1Q Loss

ARS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Stock Track | ARS Pharmaceuticals Plunges 6.37% Pre-market on Wider Q1 Loss Despite Revenue Beat

BRIEF-ARS Pharmaceuticals Q1 Operating Income USD -37.177 Million

ARS Pharmaceuticals' Q1 Net Loss Widens, Revenue Tops Estimates

MT Newswires Live

Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Net Loss $0.35 a Share, vs. FactSet Est of $0.32 Loss

MT Newswires Live

Stock Track | ARS Pharmaceuticals (SPRY) Soars 8.31% Pre-market on Better-Than-Expected Q1 Results

Stock Track | ARS Pharmaceuticals (SPRY) Soars 8.31% Pre-market on Better-than-Expected Q1 Results

ARS Pharmaceuticals Q1 EPS $(0.35) Misses $(0.33) Estimate, Sales $7.97M Beat $7.48M Estimate

ARS Pharmaceuticals Reports Q1 2025 Results: $7.8M in Neffy Sales, $33.9M Net Loss, EPS at $0.35

Press Release: ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy(R) (epinephrine nasal spray)

BRIEF-ARS Pharmaceuticals Inc Cash Price For Neffy Is $199 For Two Doses On GoodRx Website

ARS Pharmaceuticals Signs Co-Promotion Deal With ALK-Abello for Neffy Nasal Spray in US

MT Newswires Live

BRIEF-ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner And Global Allergy Leader Alk-Abello A/S

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

ALK enters into neffy® co-promotion agreement in the USA

US High Growth Tech Stocks To Watch Now

Simply Wall St.

High Insider Ownership Growth Stocks To Know In April 2025

Simply Wall St.

Stock Track | ARS Pharmaceuticals Plummets 5% as Analysts Slash Revenue and Earnings Forecasts

Stock Track | ARS Pharmaceuticals (SPRY) Plummets 5.02% as Analysts Slash 2025 Forecasts

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SPRY/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SPRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":17.925,"timestamp":1753807195104,"preClose":18.35,"halted":0,"volume":308791,"delay":0,"floatShares":53634396,"shares":98213561,"eps":-0.160792,"marketStatus":"Trading","change":-0.425,"latestTime":"07-29 12:40:06 EDT","open":18.5,"high":18.5,"low":17.875,"amount":5584953.670947,"amplitude":0.03406,"askPrice":17.93,"askSize":393,"bidPrice":17.92,"bidSize":214,"shortable":3,"etf":0,"ttmEps":-0.160792,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1753819200000},"marketStatusCode":2,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":18.35,"preHourTrading":{"tag":"盘前","latestPrice":18.54,"preClose":18.35,"latestTime":"09:27 EDT","volume":2934,"amount":54081.958428000005,"timestamp":1753795670018},"postHourTrading":{"tag":"盘后","latestPrice":18.35,"preClose":18.35,"latestTime":"19:15 EDT","volume":21252,"amount":389939.53,"timestamp":1753744531363},"volumeRatio":0.395527,"impliedVol":0.7462,"impliedVolPercentile":0.472},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","floatShares":53634396,"roa":"-6.10%","roe":"-6.91%","lyrEps":0.082507,"volumeRatio":0.395527,"shares":98213561,"dividePrice":0,"high":18.5,"amplitude":0.03406,"preClose":18.35,"low":17.875,"week52Low":8.9055,"pbRate":"7.69","psRate":"18.13","week52High":18.9,"institutionHeld":0,"latestPrice":17.925,"committee":-0.294893,"eps":-0.160792,"divideRate":0,"volume":308791,"delay":0,"ttmEps":-0.160792,"open":18.5,"prevYearClose":10.55,"prevWeekClose":17.87,"prevMonthClose":17.45,"prevQuarterClose":17.45,"fiveDayClose":17.59,"twentyDayClose":17.45,"sixtyDayClose":14.16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPRY\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535008648","title":"ARS Pharmaceuticals Falls After Wider-Than-Expected 1Q Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2535008648","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535008648?lang=en_us&edition=fundamental","pubTime":"2025-05-15 00:51","pubTimestamp":1747241460,"startTime":"0","endTime":"0","summary":"Shares of ARS Pharmaceuticals slipped after the biopharmaceutical company reported a first-quarter loss that was wider than analysts had expected.The stock was down 9%, to $12.12, in midday trading Wednesday, but has gained about 14% since the start of the year.The San Diego company reported a first-quarter loss of $34.1 million, or 35 cents a share. Analysts polled by FactSet were looking for a loss of $31.2 million, or 34 cents a share.Revenue for the quarter was $8 million, compared with the $7.5 million analysts were expecting.Product revenue from its neffy sales in the U.S. were $7.8 million, and $200,000 in revenue came from a collaboration with Denmark's ALK-Abello. Neffy is a nasal spray used for emergency treatment of allergic reactions, including anaphylaxis.ARS said it had cash, cash equivalents and short-term investments of $275.7 million as of March 31.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"ARS Pharmaceuticals Falls After Wider-Than-Expected 1Q Loss","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2535272630","title":"ARS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535272630","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535272630?lang=en_us&edition=fundamental","pubTime":"2025-05-14 21:32","pubTimestamp":1747229542,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryARS Pharmaceuticals Inc SPRY.OQ reported a quarterly adjusted loss of 35 cents per share for the quarter ended ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nL8N3RM1LS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0},{"id":"1194819562","title":"Stock Track | ARS Pharmaceuticals Plunges 6.37% Pre-market on Wider Q1 Loss Despite Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1194819562","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194819562?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:02","pubTimestamp":1747224156,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc  saw its stock price plummet 6.37% in pre-market trading following the release of its first-quarter 2025 financial results. The company reported a wider-than-expected loss, overshadowing its revenue beat and progress in the commercial launch of its flagship product, Neffy .Despite the revenue beat, investors seem concerned about the company's rising expenses. ARS Pharmaceuticals reported operating expenses of $45.15 million, with selling, general, and administrative expen","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2535025812","title":"BRIEF-ARS Pharmaceuticals Q1 Operating Income USD -37.177 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535025812","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535025812?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:53","pubTimestamp":1747223627,"startTime":"0","endTime":"0","summary":"BRIEF-ARS Pharmaceuticals Q1 Operating Income USD -37.177 Million May 14 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICALS Q1 OPERATING INCOME USD -37.177 MILLION VERSUS. IBES ESTIMATE US","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nPLX4A87C3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0},{"id":"2535402570","title":"ARS Pharmaceuticals' Q1 Net Loss Widens, Revenue Tops Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535402570","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535402570?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:26","pubTimestamp":1747221991,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  reported a Q1 net loss Wednesday of $0.35 per diluted share, wider than a loss of $0.11 a year earlier.Analysts polled by FactSet expected a loss of $0.32.Revenue for the quarter ended March 31 was $8 million.Analysts surveyed by FactSet expected $7.5 million.As of March 31, the company said it had $275.7 million in cash and cash equivalents on hand, and expected it could fund operations through the next three years.ARS' shares were 1.1% higher in premarket trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRY"],"gpt_icon":0},{"id":"2535047161","title":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Net Loss $0.35 a Share, vs. FactSet Est of $0.32 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2535047161","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535047161?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:12","pubTimestamp":1747221125,"startTime":"0","endTime":"0","summary":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Net Loss $0.35 a Share, vs. FactSet Est of $0.32 Loss","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRY"],"gpt_icon":0},{"id":"1187880914","title":"Stock Track | ARS Pharmaceuticals (SPRY) Soars 8.31% Pre-market on Better-Than-Expected Q1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1187880914","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187880914?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:02","pubTimestamp":1747220544,"startTime":"0","endTime":"0","summary":"Shares of ARS Pharmaceuticals Inc  are surging in pre-market trading on Wednesday, up 8.31% following the release of the company's first-quarter financial results. The pharmaceutical firm's stock is attracting investor attention as it outperformed analyst expectations in its latest earnings report.ARS Pharmaceuticals reported a net loss of $33.94 million for the first quarter, which was notably better than the consensus estimate of a $34.6 million loss projected by analysts polled by IBES. This ","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"1144452584","title":"Stock Track | ARS Pharmaceuticals (SPRY) Soars 8.31% Pre-market on Better-than-Expected Q1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1144452584","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144452584?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:02","pubTimestamp":1747220540,"startTime":"0","endTime":"0","summary":"Shares of ARS Pharmaceuticals Inc  surged 8.31% in pre-market trading on Wednesday, following the release of its first-quarter financial results. The pharmaceutical company's performance exceeded analysts' expectations, sparking investor optimism.ARS Pharmaceuticals reported a net loss of $33.94 million for the first quarter, which was better than the IBES estimate of a $34.6 million loss. This narrower-than-expected loss suggests that the company is managing its finances more efficiently than a","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Stock Track | ARS Pharmaceuticals (SPRY) Soars 8.31% Pre-market on Better-than-Expected Q1 Results","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2535468042","title":"ARS Pharmaceuticals Q1 EPS $(0.35) Misses $(0.33) Estimate, Sales $7.97M Beat $7.48M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535468042","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535468042?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:01","pubTimestamp":1747220518,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 6.06 percent. This is a 218.18 percent decrease over losses of $(0.11) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45402287/ars-pharmaceuticals-q1-eps-0-35-misses-0-33-estimate-sales-7-97m-beat-7-48m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0},{"id":"2535042271","title":"ARS Pharmaceuticals Reports Q1 2025 Results: $7.8M in Neffy Sales, $33.9M Net Loss, EPS at $0.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2535042271","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535042271?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220423,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. reported its financial results for the first quarter of 2025, highlighting total revenues of $8.0 million. This figure includes $7.8 million in net product revenue from sales of **_neffy_** in the U.S. and $0.2 million in collaboration revenue from ALK-Abelló A/S . The company reported a net loss of $33.9 million for the quarter. Research and development expenses amounted to $3.0 million, primarily associated with the ongoing clinical and development efforts for **_neffy_**. Selling, general, and administrative expenses were $41.1 million, largely due to personnel-related and sales and marketing expenses tied to the commercialization of **_neffy_**. ARS Pharmaceuticals also provided an update on the U.S. commercial launch of **_neffy_** , the first FDA-approved and European Commission-approved needle-free epinephrine treatment for Type I allergic reactions, including anaphylaxis. The product has been prescribed by over 5,000 physicians, demonstrating considerab","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL3D7KKC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SPRY"],"gpt_icon":0},{"id":"2535440042","title":"Press Release: ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy(R) (epinephrine nasal spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535440042","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535440042?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220400,"startTime":"0","endTime":"0","summary":"$7.8 million in total neffy U.S. net product revenue in first quarter of 2025. neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians. More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle-free treatment for severe allergic reactions including anaphylaxis. Conference call to be held today, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET. SAN DIEGO, May 14, 2025  -- ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced financial results for the first quarter of 2025 and provided an update on the continued U.S. commercial launch of neffy , the first and only FDA-approved and European Commission approved needle-free epinephri","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DTC","ALK","BK4588","BK4232","BK4023","BK4022","BK4585","BK4500","LU2065732104.USD","PRGS","SPRY","R","BK4008","BK4097","HCP","BK4190","BK4139"],"gpt_icon":0},{"id":"2533098248","title":"BRIEF-ARS Pharmaceuticals Inc Cash Price For Neffy Is $199 For Two Doses On GoodRx Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2533098248","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533098248?lang=en_us&edition=fundamental","pubTime":"2025-05-07 20:15","pubTimestamp":1746620128,"startTime":"0","endTime":"0","summary":"BRIEF-ARS Pharmaceuticals Inc Cash Price For Neffy Is $199 For Two Doses On GoodRx WebsiteMay 7 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICALS INC: CASH PRICE FOR NEFFY IS $199 FOR TWO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nFWN3RF0GE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2532339842","title":"ARS Pharmaceuticals Signs Co-Promotion Deal With ALK-Abello for Neffy Nasal Spray in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2532339842","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532339842?lang=en_us&edition=fundamental","pubTime":"2025-05-02 21:53","pubTimestamp":1746194001,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  said Friday it has signed an agreement with allergy immunotherapy firm ALK-Abello to co-promote Neffy nasal spray to up to 9,000 pediatricians in the US.Under the four-year deal, ARS will recognize all US revenue and will continue to have sole responsibility for all US commercialization activities, ARS said.ARS said it expects its operating expense outlook for 2025 to rise by about $3 million per quarter starting in Q3 under the deal but said its 2025 cash flow won't be impacted.The agreement follows a licensing deal between ARS and ALK-Abello, which provided ARS with $145 million upfront and gave ALK commercialization rights to Neffy in Canada, the UK, the EU and other countries outside the US, ARS said.Shares of ARS Pharmaceuticals were 3.5% higher in recent trading.Price: 14.55, Change: +0.39, Percent Change: +2.72","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4139","BK4585","SPRY","ALK","BK4500","BK4008"],"gpt_icon":0},{"id":"2532841603","title":"BRIEF-ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner And Global Allergy Leader Alk-Abello A/S","url":"https://stock-news.laohu8.com/highlight/detail?id=2532841603","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532841603?lang=en_us&edition=fundamental","pubTime":"2025-05-02 21:31","pubTimestamp":1746192668,"startTime":"0","endTime":"0","summary":"BRIEF-ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner And Global Allergy Leader Alk-Abello A/S May 2 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICALS ANNOUNCES CO-PROMO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nTUA5TLV7H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2532481668","title":"ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians","url":"https://stock-news.laohu8.com/highlight/detail?id=2532481668","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532481668?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187200,"startTime":"0","endTime":"0","summary":"Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European Union and certain other countries outside the United States. New partnership expands ARS Pharma’s direct promotional efforts to nearly 20,000 healthcare providers, reaching key pediatricians ahead of the back-to-school season. “As a result of broad coverage from leading pharmaceutical benefit managers and health plans, millions of patients nationwide now have improved access to neffy,” said Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma. “This partnership extension with ALK allows us to efficiently reach healthcare professionals who represent about 55% of all community-use epinephrine prescriptions in the United States. By expanding direct promotion with ALK, the global leader in allergy immunotherapy  with substantial experience in the allergy space, we ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-announces-co-promotion-120000254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4008","BK4500","BK4104","LU2065731478.USD","LU0053671581.USD","BK4588","ALK","LU1878469433.USD","SPRY","LU0054578231.USD","AIT","AKBLF","BK4585"],"gpt_icon":0},{"id":"2532184819","title":"ALK enters into neffy® co-promotion agreement in the USA","url":"https://stock-news.laohu8.com/highlight/detail?id=2532184819","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532184819?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:59","pubTimestamp":1746187140,"startTime":"0","endTime":"0","summary":"Co-promotion with ARS Pharma based on cost sharing and performance-based revenue sharing.ALK to accelerate build-up of its US paediatric sales channel in a balanced way.Agreement does not change ALK’s revenue and earnings outlook for 2025.ALK  today announced a 4-year agreement with US-based ARS Pharmaceuticals, Inc.  to co-promote the neffy adrenaline  nasal spray to up to 9,000 named paediatricians in the USA. These paediatricians currently account for close to 10% of all adrenaline auto-injector prescriptions in the USA.Commenting on the new agreement, ALK's CEO Peter Halling said: “We are excited about expanding our partnership with ARS Pharma, which we firmly consider a win-win situation for all parties. More children, caregivers, and prescribers in the USA get access to an effective and needle-free anaphylaxis treatment. Although the agreement initially will have a limited financial impact for ALK, we are strengthening our capabilities in the USA. This may also support our respir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alk-enters-neffy-co-promotion-115900482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","BK4585","BK4008","AKBLF","SPRY","EBIT","ALK","BK4588","BK4500"],"gpt_icon":0},{"id":"2525401406","title":"US High Growth Tech Stocks To Watch Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2525401406","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525401406?lang=en_us&edition=fundamental","pubTime":"2025-04-07 19:08","pubTimestamp":1744024106,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has dropped 9.4%, and over the past 12 months, it is down by 3.4%, yet earnings are expected to grow by 14% per annum in the coming years. In this environment, identifying high growth tech stocks involves looking for companies with strong fundamentals and innovative potential that can capitalize on anticipated earnings growth despite recent market volatility.Top 10 High Growth Tech Companies In The United States. Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.Operations: ARS Pharmaceuticals generates revenue primarily from its pharmaceuticals segment, amounting to $89.15 million. The company is dedicated to advancing biopharmaceutical solutions for severe allergic reactions.ARS Pharmaceuticals has demonstrated robust growth, with a revenue surge from $0.03 million to $8","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-high-growth-tech-stocks-110826024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3B42.SGD","LU1559883803.SGD","BK4532","BK4585","LU1815336091.USD","LU0757428866.USD","VRTX","IE00B4R5TH58.HKD","BK4023","CLSKW","LU1069344957.HKD","LU2236285917.USD","LU2362541513.USD","CLSK","VERX","IE00B19Z9P08.USD","LU1430594728.SGD","SPRY","LU0289739699.SGD","IE00B19Z9Z06.USD","LU0234570918.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0058720904.USD","LU2362540622.SGD","LU2362541273.HKD","IE0009355771.USD","IE0002270589.USD","BK4588","LU1093756168.USD","LU0109394709.USD","LU0079474960.USD","LU1093756325.SGD","LU2237438978.USD","SGXZ57979304.SGD","LU1585245621.USD","LU2417539215.USD","BK4567","SG9999001176.SGD","LU0566484027.USD","SG9999013999.USD","LU0256863811.USD","LU0417517546.SGD","LU1035775433.USD","LU2462157665.USD","IE00B19Z3581.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","SG9999001176.USD","LU0889565916.HKD","LU0061475181.USD"],"gpt_icon":0},{"id":"2524669258","title":"High Insider Ownership Growth Stocks To Know In April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524669258","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524669258?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:06","pubTimestamp":1743678379,"startTime":"0","endTime":"0","summary":"As the U.S. market navigates through a period of volatility fueled by recent tariff announcements, investors are keeping a keen eye on companies that can withstand economic headwinds. In this environment, growth stocks with high insider ownership often stand out as they suggest strong confidence from those closest to the company, potentially offering resilience and alignment with shareholder interests.Top 10 Growth Companies With High Insider Ownership In The United States. Underneath we present a selection of stocks filtered out by our screen.Overview: Joint Stock Company Kaspi.kz, with a market cap of $17.92 billion, offers payments, marketplace, and fintech solutions for consumers and merchants in Kazakhstan, Azerbaijan, and Ukraine.Operations: The company's revenue segments consist of Fintech at 1.28 billion KZT, Payments at 587.10 million KZT, and Marketplace at 732.94 million KZT.Kaspi.kz's earnings are expected to grow at 15.8% annually, surpassing the US market","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-insider-ownership-growth-stocks-110619013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU1720051017.SGD","BK4196","BK4588","LU1548497426.USD","LU2065171311.SGD","LU2065169927.USD","LU1720051108.HKD","BK4539","BK4113","BK4097","TBBB","BK4613","KSPI","MNDY","LU2065170008.USD","LU2357305700.SGD","BK4585","SPRY","LU2065171402.SGD"],"gpt_icon":1},{"id":"1179611170","title":"Stock Track | ARS Pharmaceuticals Plummets 5% as Analysts Slash Revenue and Earnings Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=1179611170","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179611170?lang=en_us&edition=fundamental","pubTime":"2025-03-27 00:30","pubTimestamp":1743006628,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc.  saw its stock plummet 5.02% during intraday trading on Wednesday, following a series of downgraded forecasts from analysts. The sharp decline comes as market experts paint a gloomy picture for the company's near-term financial performance.According to the latest analyst reports, ARS Pharmaceuticals is facing significant headwinds in its revenue and earnings projections. The consensus forecast for 2025 revenues has been drastically reduced from US$125 million to US$83 mi","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"1103304234","title":"Stock Track | ARS Pharmaceuticals (SPRY) Plummets 5.02% as Analysts Slash 2025 Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=1103304234","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103304234?lang=en_us&edition=fundamental","pubTime":"2025-03-27 00:30","pubTimestamp":1743006625,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc.  saw its stock plummet 5.02% during Wednesday's intraday trading session, following a series of analyst downgrades that have raised concerns about the company's future performance. The sharp decline comes as a stark contrast to the stock's recent 14% gain over the past week.Analysts have significantly cut their revenue and earnings forecasts for ARS Pharmaceuticals in 2025. The consensus revenue estimate has been reduced from $125 million to $83 million, representing a 6","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | ARS Pharmaceuticals (SPRY) Plummets 5.02% as Analysts Slash 2025 Forecasts","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":83,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"SPRY","fiscalQuarterEnding":"2025/03","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"pre","actualEps":-0.35},{"market":"US","date":"2025-03-20","symbol":"SPRY","fiscalQuarterEnding":"2024/12","expectedEps":-0.04,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"pre","actualEps":0.52},{"market":"US","date":"2025-01-13","symbol":"SPRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1736744400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"SPRY","fiscalQuarterEnding":"2024/09","expectedEps":-0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":-0.2},{"market":"US","date":"2024-08-06","symbol":"SPRY","fiscalQuarterEnding":"2024/06","expectedEps":-0.12,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"post","actualEps":-0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPRY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1741492800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPRY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPRY","date":"2025-07-28","current":-112.145453,"percent":0.01372,"low":-115.157754,"twenty":-30.612951,"median":-18.17176,"eighty":-11.985677,"high":184.020638,"avg":-15.546733,"sd":50.759131,"marketCap":1755076335},"quantilePoints":[{"date":"2022-11-11","current":-28.534516,"twenty":-28.349227,"median":-28.071294,"eighty":-27.904534,"marketCap":577624216},{"date":"2022-11-18","current":-27.515427,"twenty":-28.349227,"median":-28.00181,"eighty":-27.867476,"marketCap":556994780},{"date":"2022-11-25","current":-28.627161,"twenty":-29.164499,"median":-28.302905,"eighty":-27.978649,"marketCap":579499619},{"date":"2022-12-02","current":-32.332942,"twenty":-29.813011,"median":-28.534516,"eighty":-27.978649,"marketCap":654515751},{"date":"2022-12-09","current":-33.352032,"twenty":-32.629404,"median":-28.951417,"eighty":-27.987913,"marketCap":675145188},{"date":"2022-12-16","current":-37.428392,"twenty":-33.870842,"median":-29.970507,"eighty":-28.034236,"marketCap":757662933},{"date":"2022-12-23","current":-37.428392,"twenty":-36.761351,"median":-31.221208,"eighty":-28.136145,"marketCap":757662933},{"date":"2022-12-30","current":-39.512894,"twenty":-37.428392,"median":-32.842487,"eighty":-28.39555,"marketCap":799859507},{"date":"2023-01-06","current":-33.490999,"twenty":-37.558094,"median":-33.236227,"eighty":-28.506723,"marketCap":677958292},{"date":"2023-01-13","current":-34.510089,"twenty":-37.428392,"median":-33.352032,"eighty":-28.608632,"marketCap":698587729},{"date":"2023-01-20","current":-24.704541,"twenty":-37.261632,"median":-32.981454,"eighty":-28.089644,"marketCap":627322403},{"date":"2023-01-27","current":-23.338221,"twenty":-36.955904,"median":-32.518231,"eighty":-27.978649,"marketCap":592627442},{"date":"2023-02-03","current":-26.292426,"twenty":-36.631648,"median":-30.109473,"eighty":-26.233342,"marketCap":667643574},{"date":"2023-02-10","current":-28.323442,"twenty":-36.44636,"median":-29.576768,"eighty":-26.233342,"marketCap":719217165},{"date":"2023-02-17","current":-31.868488,"twenty":-36.103575,"median":-29.970507,"eighty":-27.026227,"marketCap":809236523},{"date":"2023-02-24","current":-30.539096,"twenty":-35.51065,"median":-30.109473,"eighty":-27.543213,"marketCap":775479264},{"date":"2023-03-03","current":-33.641011,"twenty":-34.760229,"median":-30.612951,"eighty":-27.668279,"marketCap":854246203},{"date":"2023-03-10","current":-29.025066,"twenty":-34.306271,"median":-30.649879,"eighty":-27.867476,"marketCap":737033496},{"date":"2023-03-17","current":-31.056082,"twenty":-33.963486,"median":-30.631415,"eighty":-27.978649,"marketCap":788607087},{"date":"2023-03-24","current":-20.659679,"twenty":-33.801144,"median":-30.612951,"eighty":-27.867476,"marketCap":716518982},{"date":"2023-03-31","current":-17.719962,"twenty":-33.618064,"median":-30.576023,"eighty":-26.2038,"marketCap":614563712},{"date":"2023-04-06","current":-15.732931,"twenty":-33.565575,"median":-30.176574,"eighty":-25.70897,"marketCap":545649501},{"date":"2023-04-14","current":-16.631178,"twenty":-33.492841,"median":-29.970507,"eighty":-24.113699,"marketCap":576802501},{"date":"2023-04-21","current":-17.973502,"twenty":-33.463206,"median":-29.344076,"eighty":-23.419462,"marketCap":623356984},{"date":"2023-04-28","current":-17.210989,"twenty":-33.352032,"median":-29.090384,"eighty":-19.070054,"marketCap":596911536},{"date":"2023-05-05","current":-16.693286,"twenty":-33.350744,"median":-28.918758,"eighty":-18.073817,"marketCap":578956528},{"date":"2023-05-12","current":-12.329028,"twenty":-33.323434,"median":-28.627161,"eighty":-17.841072,"marketCap":427595344},{"date":"2023-05-19","current":-17.294264,"twenty":-33.212652,"median":-28.359496,"eighty":-17.789501,"marketCap":733155735},{"date":"2023-05-26","current":-17.057707,"twenty":-33.123305,"median":-28.101877,"eighty":-17.789501,"marketCap":723127390},{"date":"2023-06-02","current":-15.358643,"twenty":-33.120421,"median":-28.024971,"eighty":-17.719962,"marketCap":651098973},{"date":"2023-06-09","current":-15.179795,"twenty":-32.981454,"median":-27.978649,"eighty":-17.665522,"marketCap":643517035},{"date":"2023-06-16","current":-13.525443,"twenty":-32.939388,"median":-27.584891,"eighty":-17.230009,"marketCap":573384103},{"date":"2023-06-23","current":-14.352619,"twenty":-32.898926,"median":-26.292426,"eighty":-16.984823,"marketCap":608450569},{"date":"2023-06-30","current":-14.777385,"twenty":-32.852687,"median":-26.033933,"eighty":-16.443167,"marketCap":626457673},{"date":"2023-07-07","current":-14.374975,"twenty":-32.778571,"median":-25.664657,"eighty":-16.200645,"marketCap":609398311},{"date":"2023-07-14","current":-15.381,"twenty":-32.650157,"median":-24.815323,"eighty":-15.896248,"marketCap":652046716},{"date":"2023-07-20","current":-16.342312,"twenty":-32.522678,"median":-23.947525,"eighty":-15.738555,"marketCap":692799635},{"date":"2023-07-28","current":-14.889165,"twenty":-32.268091,"median":-23.449004,"eighty":-15.666005,"marketCap":631196385},{"date":"2023-08-04","current":-15.649273,"twenty":-31.980646,"median":-22.434463,"eighty":-15.664922,"marketCap":663419624},{"date":"2023-08-11","current":-12.27233,"twenty":-31.772476,"median":-20.321699,"eighty":-15.577733,"marketCap":654642902},{"date":"2023-08-18","current":-12.05734,"twenty":-31.358888,"median":-18.902086,"eighty":-15.443597,"marketCap":643174706},{"date":"2023-08-25","current":-12.361909,"twenty":-31.218563,"median":-18.499284,"eighty":-15.287104,"marketCap":659421318},{"date":"2023-08-30","current":-12.70231,"twenty":-31.152094,"median":-18.359623,"eighty":-15.152968,"marketCap":677579296},{"date":"2023-09-08","current":-13.114373,"twenty":-31.100395,"median":-18.231502,"eighty":-15.005417,"marketCap":699560007},{"date":"2023-09-15","current":-13.04271,"twenty":-31.033926,"median":-18.031385,"eighty":-14.777385,"marketCap":695737274},{"date":"2023-09-20","current":-11.833393,"twenty":-31.022847,"median":-18.002563,"eighty":-14.750557,"marketCap":631228667},{"date":"2023-09-27","current":-6.718429,"twenty":-31.011769,"median":-17.988032,"eighty":-14.670075,"marketCap":358381151},{"date":"2023-10-05","current":-7.166324,"twenty":-30.867751,"median":-17.964938,"eighty":-14.419687,"marketCap":382273228},{"date":"2023-10-13","current":-6.718429,"twenty":-30.668342,"median":-17.875755,"eighty":-14.196126,"marketCap":358381151},{"date":"2023-10-20","current":-6.055544,"twenty":-30.649879,"median":-17.782874,"eighty":-14.047454,"marketCap":323020877},{"date":"2023-10-27","current":-6.306365,"twenty":-30.649879,"median":-17.728408,"eighty":-14.012806,"marketCap":336400440},{"date":"2023-11-03","current":-6.539271,"twenty":-30.635108,"median":-17.710569,"eighty":-13.713234,"marketCap":348824320},{"date":"2023-11-10","current":-5.319172,"twenty":-30.612951,"median":-17.665522,"eighty":-13.225451,"marketCap":327799293},{"date":"2023-11-17","current":-7.025405,"twenty":-30.612951,"median":-17.36121,"eighty":-12.859969,"marketCap":432947606},{"date":"2023-11-24","current":-7.41484,"twenty":-30.59818,"median":-17.220775,"eighty":-12.627063,"marketCap":456946919},{"date":"2023-12-01","current":-7.523882,"twenty":-30.480012,"median":-17.057707,"eighty":-12.494486,"marketCap":463666727},{"date":"2023-12-08","current":-8.1314,"twenty":-30.216835,"median":-16.553813,"eighty":-12.335604,"marketCap":501105655},{"date":"2023-12-15","current":-8.115823,"twenty":-30.090944,"median":-16.431736,"eighty":-12.243664,"marketCap":500145682},{"date":"2023-12-22","current":-7.944471,"twenty":-30.007565,"median":-16.309818,"eighty":-8.996418,"marketCap":489585985},{"date":"2023-12-29","current":-8.770073,"twenty":-29.979771,"median":-16.222884,"eighty":-8.287174,"marketCap":540464528},{"date":"2024-01-05","current":-8.785651,"twenty":-29.917293,"median":-16.174641,"eighty":-8.399331,"marketCap":541424501},{"date":"2024-01-12","current":-9.112776,"twenty":-29.704533,"median":-16.005127,"eighty":-8.58626,"marketCap":561583924},{"date":"2024-01-19","current":-9.471056,"twenty":-29.440705,"median":-15.977907,"eighty":-8.629876,"marketCap":583663292},{"date":"2024-01-26","current":-10.156461,"twenty":-29.180978,"median":-15.857321,"eighty":-8.707763,"marketCap":625902083},{"date":"2024-02-02","current":-9.969533,"twenty":-29.156298,"median":-15.732931,"eighty":-8.773189,"marketCap":614382412},{"date":"2024-02-09","current":-10.109729,"twenty":-29.07732,"median":-15.682807,"eighty":-8.798113,"marketCap":623022165},{"date":"2024-02-16","current":-11.309188,"twenty":-29.025066,"median":-15.649273,"eighty":-8.900923,"marketCap":696940049},{"date":"2024-02-23","current":-11.83882,"twenty":-29.025066,"median":-15.515136,"eighty":-9.112776,"marketCap":729579115},{"date":"2024-03-01","current":-13.038279,"twenty":-28.81245,"median":-15.453657,"eighty":-9.20624,"marketCap":803496999},{"date":"2024-03-08","current":-13.941768,"twenty":-28.8035,"median":-15.381,"eighty":-9.20624,"marketCap":859175405},{"date":"2024-03-15","current":-14.019655,"twenty":-28.627161,"median":-15.258041,"eighty":-9.237395,"marketCap":863975268},{"date":"2024-03-22","current":-15.975609,"twenty":-28.534516,"median":-15.179795,"eighty":-9.252972,"marketCap":868513986},{"date":"2024-03-28","current":-17.679674,"twenty":-28.423343,"median":-15.269219,"eighty":-9.315282,"marketCap":961155477},{"date":"2024-04-05","current":-16.916395,"twenty":-28.337864,"median":-15.369822,"eighty":-9.405631,"marketCap":919659809},{"date":"2024-04-12","current":-16.401625,"twenty":-28.264358,"median":-15.43689,"eighty":-9.46171,"marketCap":891674358},{"date":"2024-04-19","current":-14.981571,"twenty":-28.131419,"median":-15.49278,"eighty":-9.483518,"marketCap":814473115},{"date":"2024-04-26","current":-14.360297,"twenty":-28.077411,"median":-15.403356,"eighty":-9.636176,"marketCap":780697571},{"date":"2024-05-03","current":-16.860498,"twenty":-28.034236,"median":-15.420123,"eighty":-9.72341,"marketCap":916620967},{"date":"2024-05-10","current":-17.157732,"twenty":-27.987913,"median":-15.505955,"eighty":-9.779488,"marketCap":852670667},{"date":"2024-05-17","current":-17.742813,"twenty":-27.978649,"median":-15.537492,"eighty":-9.809086,"marketCap":881746829},{"date":"2024-05-24","current":-17.157885,"twenty":-27.978649,"median":-15.649273,"eighty":-9.876069,"marketCap":852678252},{"date":"2024-05-31","current":-17.313866,"twenty":-27.867476,"median":-15.716341,"eighty":-9.910338,"marketCap":860429873},{"date":"2024-06-07","current":-17.177383,"twenty":-27.668279,"median":-15.746992,"eighty":-9.932147,"marketCap":853647205},{"date":"2024-06-14","current":-16.884919,"twenty":-27.543213,"median":-15.872834,"eighty":-9.957071,"marketCap":839112916},{"date":"2024-06-21","current":-15.929536,"twenty":-27.026227,"median":-15.872834,"eighty":-9.981995,"marketCap":791634241},{"date":"2024-06-28","current":-16.592455,"twenty":-26.233342,"median":-15.857321,"eighty":-10.038073,"marketCap":824578628},{"date":"2024-07-05","current":-17.742813,"twenty":-26.122559,"median":-15.901185,"eighty":-10.097267,"marketCap":881746829},{"date":"2024-07-12","current":-22.129772,"twenty":-26.004391,"median":-15.977907,"eighty":-10.112844,"marketCap":1099761155},{"date":"2024-07-19","current":-20.550467,"twenty":-25.84191,"median":-16.008119,"eighty":-10.131537,"marketCap":1021275998},{"date":"2024-07-26","current":-21.408361,"twenty":-25.598187,"median":-16.06602,"eighty":-10.234348,"marketCap":1063909910},{"date":"2024-08-02","current":-19.302621,"twenty":-25.251068,"median":-16.155521,"eighty":-10.620668,"marketCap":959263034},{"date":"2024-08-09","current":-23.520911,"twenty":-24.881793,"median":-16.206368,"eighty":-10.941562,"marketCap":1054724705},{"date":"2024-08-16","current":-28.81744,"twenty":-25.84191,"median":-16.286222,"eighty":-11.035026,"marketCap":1292231647},{"date":"2024-08-23","current":-28.017556,"twenty":-27.270827,"median":-16.393243,"eighty":-11.081758,"marketCap":1256363252},{"date":"2024-08-30","current":-28.060793,"twenty":-27.941591,"median":-16.401625,"eighty":-11.197031,"marketCap":1258302084},{"date":"2024-09-06","current":-24.558599,"twenty":-27.79336,"median":-16.442915,"eighty":-11.309188,"marketCap":1101256678},{"date":"2024-09-13","current":-28.752585,"twenty":-27.79336,"median":-16.472628,"eighty":-11.620736,"marketCap":1289323399},{"date":"2024-09-20","current":-31.930502,"twenty":-27.995938,"median":-16.576918,"eighty":-11.620736,"marketCap":1431827564},{"date":"2024-09-27","current":-30.95767,"twenty":-28.060793,"median":-16.631178,"eighty":-11.714201,"marketCap":1388203840},{"date":"2024-10-04","current":-30.67663,"twenty":-28.212122,"median":-16.751589,"eighty":-11.833393,"marketCap":1375601431},{"date":"2024-10-11","current":-31.39004,"twenty":-28.39555,"median":-16.860498,"eighty":-11.83882,"marketCap":1407592162},{"date":"2024-10-18","current":-34.567957,"twenty":-28.752585,"median":-16.884919,"eighty":-11.967761,"marketCap":1550096327},{"date":"2024-10-25","current":-31.930502,"twenty":-28.968769,"median":-17.021402,"eighty":-12.05734,"marketCap":1431827564},{"date":"2024-11-01","current":-32.989808,"twenty":-29.172776,"median":-17.10772,"eighty":-12.236498,"marketCap":1479328953},{"date":"2024-11-08","current":-36.837898,"twenty":-29.53085,"median":-17.177383,"eighty":-12.27233,"marketCap":1651885017},{"date":"2024-11-15","current":-27.728261,"twenty":-29.574087,"median":-17.203935,"eighty":-12.290246,"marketCap":1361568504},{"date":"2024-11-22","current":-27.708469,"twenty":-29.53085,"median":-17.216378,"eighty":-12.329028,"marketCap":1360596650},{"date":"2024-11-29","current":-28.717849,"twenty":-29.510269,"median":-17.294264,"eighty":-12.329028,"marketCap":1410161242},{"date":"2024-12-06","current":-27.748052,"twenty":-29.318167,"median":-17.323614,"eighty":-12.355333,"marketCap":1362540359},{"date":"2024-12-13","current":-23.552198,"twenty":-29.200708,"median":-17.377363,"eighty":-12.390575,"marketCap":1156507152},{"date":"2024-12-20","current":-22.127191,"twenty":-29.174826,"median":-17.429503,"eighty":-12.426406,"marketCap":1086533610},{"date":"2024-12-27","current":-21.355313,"twenty":-29.123341,"median":-17.460097,"eighty":-12.465821,"marketCap":1048631275},{"date":"2025-01-03","current":-22.146983,"twenty":-29.064257,"median":-17.508842,"eighty":-12.501652,"marketCap":1087505465},{"date":"2025-01-10","current":-22.245942,"twenty":-29.025066,"median":-17.556082,"eighty":-12.530317,"marketCap":1092364739},{"date":"2025-01-17","current":-24.878247,"twenty":-29.013807,"median":-17.625827,"eighty":-12.566149,"marketCap":1221621420},{"date":"2025-01-24","current":-27.866803,"twenty":-28.968769,"median":-17.665522,"eighty":-12.594815,"marketCap":1368371488},{"date":"2025-01-31","current":-25.768876,"twenty":-28.968769,"median":-17.692748,"eighty":-12.61273,"marketCap":1265354884},{"date":"2025-02-07","current":-23.591782,"twenty":-28.81744,"median":-17.719962,"eighty":-12.684394,"marketCap":1158450862},{"date":"2025-02-14","current":-23.7897,"twenty":-28.81245,"median":-17.725862,"eighty":-12.70231,"marketCap":1168169409},{"date":"2025-02-21","current":-22.245942,"twenty":-28.80529,"median":-17.742813,"eighty":-12.730975,"marketCap":1092364739},{"date":"2025-02-28","current":-20.741768,"twenty":-28.766646,"median":-17.750677,"eighty":-12.878556,"marketCap":1018503778},{"date":"2025-03-07","current":-21.474063,"twenty":-28.753554,"median":-17.783612,"eighty":-12.988431,"marketCap":1054462403},{"date":"2025-03-14","current":-23.492823,"twenty":-28.724796,"median":-17.918291,"eighty":-13.032048,"marketCap":1153591588},{"date":"2025-03-21","current":151.633005,"twenty":-28.645299,"median":-17.929848,"eighty":-12.988431,"marketCap":1212760777},{"date":"2025-03-28","current":153.227851,"twenty":-28.604711,"median":-17.78435,"eighty":-12.670061,"marketCap":1225516351},{"date":"2025-04-04","current":157.030944,"twenty":-28.551598,"median":-17.756493,"eighty":-12.515985,"marketCap":1255933491},{"date":"2025-04-11","current":172.365997,"twenty":-28.537065,"median":-17.742813,"eighty":-12.355333,"marketCap":1378583246},{"date":"2025-04-17","current":182.548472,"twenty":-28.53527,"median":-17.728408,"eighty":-12.28308,"marketCap":1460022683},{"date":"2025-04-25","current":168.930945,"twenty":-28.478265,"median":-17.719962,"eighty":-11.916185,"marketCap":1351109701},{"date":"2025-05-02","current":177.55989,"twenty":-28.413636,"median":-17.701176,"eighty":-11.620736,"marketCap":1420124003},{"date":"2025-05-09","current":165.034919,"twenty":-28.363303,"median":-17.672598,"eighty":-11.047488,"marketCap":1319949281},{"date":"2025-05-16","current":-85.348526,"twenty":-28.478265,"median":-17.679674,"eighty":-10.985179,"marketCap":1335704429},{"date":"2025-05-23","current":-91.122103,"twenty":-28.610323,"median":-17.701176,"eighty":-11.047488,"marketCap":1426060905},{"date":"2025-05-30","current":-97.209461,"twenty":-28.755493,"median":-17.719962,"eighty":-11.103567,"marketCap":1521328059},{"date":"2025-06-06","current":-84.344425,"twenty":-28.908237,"median":-17.728408,"eighty":-11.22507,"marketCap":1319990259},{"date":"2025-06-13","current":-90.369027,"twenty":-29.139819,"median":-17.742813,"eighty":-11.433807,"marketCap":1414275278},{"date":"2025-06-20","current":-99.845224,"twenty":-29.414401,"median":-17.756493,"eighty":-11.620736,"marketCap":1562577755},{"date":"2025-06-27","current":-113.463334,"twenty":-29.625971,"median":-17.78435,"eighty":-11.639429,"marketCap":1775701182},{"date":"2025-07-03","current":-103.673356,"twenty":-29.970507,"median":-17.918291,"eighty":-11.714201,"marketCap":1622488027},{"date":"2025-07-11","current":-112.835772,"twenty":-30.109473,"median":-17.96922,"eighty":-11.833393,"marketCap":1765879826},{"date":"2025-07-18","current":-115.157754,"twenty":-30.373971,"median":-18.060207,"eighty":-11.83882,"marketCap":1802218844},{"date":"2025-07-25","current":-112.459234,"twenty":-30.612951,"median":-18.156476,"eighty":-11.967761,"marketCap":1759987013},{"date":"2025-07-28","current":-112.145453,"twenty":-30.612951,"median":-18.17176,"eighty":-11.985677,"marketCap":1755076335}],"updateTime":1753807206602}}}